CNS Pharmaceuticals Inc. (CNSP)
The price, the headline numbers and the latest news, in one place.
CNS Pharmaceuticals Inc. (CNSP) Stock Price, Analysis & Data
| Bid | 4.18 |
| Market Cap | 8.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.7M |
| 0.98 | |
| -15.39 | |
| n/a | |
| -14.95 | |
| P/B (ttm) | 0.47 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 7.62 |
| Volume | 7,867 |
| Avg. Volume (20D) | 28,530 |
| Open | 5.96 |
| Previous Close | 6.00 |
| Day's Range | 5.83 - 6.05 |
| 52-Week Range | 1.90 - 10.59 |
| Analyst | n/a |
| Price Target | 10 (71.53%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investig...
Financial Performance
In 2025, CNS Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -15.85M, an increase of 6.68%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CNSP stock is "null". The 12-month stock price forecast is 10, which is upside of 71.53% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.38 misses estimates by -0.14, with 94.08% YoY growth.
